dalteparin has been researched along with Cancer of Gastrointestinal Tract in 8 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 9.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 8.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| "Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome." | 5.51 | Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019) |
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 5.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 4.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| "Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome." | 1.51 | Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, M | 1 |
| Harris, S | 1 |
| Underhill, C | 1 |
| Torres, J | 1 |
| Sharma, S | 1 |
| Lee, N | 1 |
| Wong, H | 1 |
| Eek, R | 1 |
| Michael, M | 1 |
| Tie, J | 1 |
| Rogers, J | 1 |
| Heriot, AG | 1 |
| Ball, D | 1 |
| MacManus, M | 1 |
| Wolfe, R | 1 |
| Solomon, BJ | 1 |
| Burbury, K | 1 |
| Dziri, C | 1 |
| Ben Hmida, W | 1 |
| Dougaz, W | 1 |
| Khalfallah, M | 1 |
| Samaali, I | 1 |
| Jerraya, H | 1 |
| Bouasker, I | 1 |
| Nouira, R | 1 |
| Obitsu, T | 1 |
| Tanaka, N | 1 |
| Oyama, A | 1 |
| Ueno, T | 1 |
| Saito, M | 1 |
| Yamaguchi, T | 1 |
| Takagi, A | 1 |
| Rikiyama, T | 1 |
| Unno, M | 1 |
| Naitoh, T | 1 |
| Houghton, DE | 1 |
| Vlazny, DT | 1 |
| Casanegra, AI | 1 |
| Brunton, N | 1 |
| Froehling, DA | 1 |
| Meverden, RA | 1 |
| Hodge, DO | 1 |
| Peterson, LG | 1 |
| McBane, RD | 1 |
| Wysokinski, WE | 1 |
| Ladha, A | 1 |
| Alam, A | 1 |
| Idestrup, C | 1 |
| Sawyer, J | 1 |
| Choi, S | 1 |
| Ageno, W | 1 |
| Vedovati, MC | 1 |
| Cohen, A | 1 |
| Huisman, M | 1 |
| Bauersachs, R | 1 |
| Gussoni, G | 1 |
| Becattini, C | 1 |
| Agnelli, G | 1 |
| Abdel-Razeq, H | 1 |
| Finianos, A | 1 |
| Taher, AT | 1 |
| Connell, NT | 1 |
| Connors, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered[NCT03504007] | 10,000 participants (Anticipated) | Observational | 2013-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dalteparin; Gastrointestinal Neoplasms; Humans; | 2018 |
3 trials available for dalteparin and Cancer of Gastrointestinal Tract
4 other studies available for dalteparin and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; Biomarkers; Enoxaparin; Gastrointestinal Neoplasms; Hemorrhage; Humans; | 2023 |
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Topics: Enoxaparin; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Liver Neop | 2021 |
Spinal haematoma after removal of a thoracic epidural catheter in a patient with coagulopathy resulting from unexpected vitamin K deficiency.
Topics: Aged; Analgesia, Epidural; Anesthesia, General; Anticoagulants; Blood Coagulation Disorders; Blood C | 2013 |
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Gastrointestinal Neoplasms; Humans; Markov Chains | 2019 |